Leveraging the HIV Vaccine Enterprise for COVID-19 Vaccine Research

- Understanding retroviruses: Tools that can analyze RNA viruses at the molecular level.
- Vaccine administration: How vaccines get into the body
  Innovative injection approaches to improve immune responses.
- Vaccine platforms: How vaccines prompt the immune system
  Innovative methods for antigen presentation to improve immune responses and vaccine durability.
- Immune system research: Decades of research into how RNA viruses and the immune system interact.
- Community engagement: Good Participatory Practices (GPP) pioneered in HIV research are informing COVID-19 research.
- Research collaboration: Building research collaboratives to speed R&D, share data and harmonize processes.
- Clinical research capacity: Leveraging existing HIV vaccine clinical trial site experience and capacity.
- Funding collaborations: Mobilizing HIV vaccine funders and funding mechanisms for accelerated COVID-19 vaccine development.

AVAC
25 Years and Counting
May, 18 2020
avac.org